Cytek Biosciences/$CTKB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Ticker
$CTKB
Sector
Primary listing
Employees
688
Headquarters
Website
CTKB Metrics
BasicAdvanced
$511M
-
-$0.05
1.34
-
Price and volume
Market cap
$511M
Beta
1.34
52-week high
$7.30
52-week low
$2.37
Average daily volume
862K
Financial strength
Current ratio
5.225
Quick ratio
4.35
Long term debt to equity
3.949
Total debt to equity
6.272
Interest coverage (TTM)
-226.62%
Profitability
EBITDA (TTM)
-21.991
Gross margin (TTM)
54.42%
Net profit margin (TTM)
-3.27%
Operating margin (TTM)
-15.03%
Effective tax rate (TTM)
15.34%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-3.77%
Return on equity (TTM)
-1.67%
Valuation
Price to revenue (TTM)
2.642
Price to book
1.35
Price to tangible book (TTM)
1.49
Price to free cash flow (TTM)
47.987
Free cash flow yield (TTM)
2.08%
Free cash flow per share (TTM)
0.084
Growth
Revenue change (TTM)
-0.85%
Earnings per share change (TTM)
-64.02%
3-year revenue growth (CAGR)
9.70%
3-year earnings per share growth (CAGR)
34.20%
What the Analysts think about CTKB
Analyst ratings (Buy, Hold, Sell) for Cytek Biosciences stock.
Bulls say / Bears say
Cytek expanded its installed base to 3,295 instruments in Q2 2025, adding 146 units and achieving 3% year-over-year unit growth, underscoring strong market adoption of its FSP technology (GlobeNewswire).
In Q2 2025, recurring revenue from services and reagents grew 16% year-over-year to comprise 32% of trailing 12-month total revenue, enhancing revenue stability and visibility (Comtex).
As of June 30, 2025, Cytek held $262.0 million in cash and marketable securities, providing ample liquidity to fund operations and future R&D investments (Nasdaq).
Total revenue for Q2 2025 declined 2% year-over-year to $45.6 million, reflecting ongoing softness in instrument sales in EMEA and APAC markets (GlobeNewswire).
The company reported a net loss of $5.6 million in Q2 2025, indicating persistent profitability challenges despite improving operational leverage (Nasdaq).
Cytek narrowed its full-year 2025 revenue guidance to $196 million–$205 million, implying potential flat to 2% growth, which may disappoint investors seeking stronger expansion (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
CTKB Financial Performance
Revenues and expenses
CTKB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytek Biosciences stock?
Cytek Biosciences (CTKB) has a market cap of $511M as of October 17, 2025.
What is the P/E ratio for Cytek Biosciences stock?
The price to earnings (P/E) ratio for Cytek Biosciences (CTKB) stock is 0 as of October 17, 2025.
Does Cytek Biosciences stock pay dividends?
No, Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Cytek Biosciences dividend payment date?
Cytek Biosciences (CTKB) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytek Biosciences?
Cytek Biosciences (CTKB) has a beta rating of 1.34. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.